INTRODUCTION
Leiomyoma are benign smooth muscle neoplasm's that typically originate from the myometrium. Their incidence among women is generally cited as 20 to 25 percent, but has been shown to be as high as 70 to 80 percent in studies using histological or sonographic examination. [1] [2] [3] [4] Submucous fibroids are the most common anatomical cause of abnormal uterine bleeding in women of reproductive age. Other symptoms related to submucous fibroids are, infertility, and postmenopausal bleeding. Advances in operative hysteroscopy have enabled removal of these lesions with a significant reduction in morbidity, post-operative recovery time and costs compared to open abdominal myomectomy. 5 This study was conducted to evaluate if large submucous fibroids could be resected in single sitting with surgeons expertise and use of prostaglandin during the procedure.
METHODS
A prospective study was undertaken from March 2007 to April 2013. The patients admitted for myomectomy for submucous fibroid were taken into consideration. A total of 38 patients were included in the present study. All of them had submucous fibroid.
11 cases had infertility associated. Rest all had menorrhagia. In these patients hysteroscopic myomectomy with a resectoscope was done. Procedures Department of Obstetrics and Gynecology, PGIMSR, ESI, Basaidarapur, New Delhi, India Pre-operative evaluation was done with transvaginal ultrasound and MRI. Patients were grouped depending on the size of fibroid. Maximum number of cases had a fibroid size between 1-5 cm in size, 8 women had fibroid of size between 9-11 cm. All these had <50% intramural extension. All cases were planned for elective hysteroscopic myomectomy. All patients underwent hysteroscopic resection with a monopolar loop. Operating surgeon was common in all these women. 1.5% glycine was used as the distending media.
Intramuscular prostaglandin injection was used in all the women after excising more than half of the myoma during surgery. Follow up was done up to maximum of 12 months post-surgery.
RESULTS
Maximum numbers of cases were in the age group of 30-40 years (42.10%). Seven were between 40-50 years of age as shown in Table 1 . Out of 38, twenty seven (71.05%) came with abnormal uterine bleeding, 11 (28.94%) had primary and secondary infertility related to submucous myoma. Three cases had severe dysmenorrhoea, due to myoma ( Table 2 ). Eight cases had been treated preoperatively with 3 doses of Growth hormone releasing hormone agonist (GNRH), as in these cases menorrhagia had led to severe iron deficiency anaemia prior to surgery. Three had blood transfusion in preoperative phase. Pre-operative evaluation was done with transvaginal ultrasound and MRI. Patients were grouped depending on the size of fibroid. Maximum number of cases had a fibroid size between 1-5 cm in size, in eight cases had fibroid of size between 9-11 cm. Eight cases were type 0 under Wamsteker classification, 26 were type 1 and 5 had type 2 myoma. All cases were planned for elective hysteroscopic myomectomy (Table 3) . 
DISCUSSION
The ability to remove these myoma depends on the degree to which myoma are embedded in the myometrium. Various classification are given to grade and grading basically decides the operability, as given by Wamsteker, et al. Type 0 myoma, the myoma completely lies in endometrial cavity are usually easy to remove. Type I lesions that is > than 50% lies in endometrial cavity and it can often be completely removed as the uterus contracts and tends to expel the intramural component into the uterine cavity during surgery However, removal of type II that is >50% lies in intramural part-myoma can be problematic, as fluid overload or fear of perforation may lead to incomplete resection. Wamsteker et al found that the likelihood of achieving a complete removal of type II myoma was only 50%. Although incomplete removal is associated with failure of treatment, there are some reports suggesting that residual tissue may undergo spontaneous regression, without the need for subsequent surgery. 5 Lasmar too developed a classification system (STEP-w) for hysteroscopic myomectomies based on the degree of technical difficulty in carrying out the procedure and to recommend the most suitable course of action in each situation. According to this classification maximum scores are given to myoma of more than 5 cm, involving upper part of uterus, covering more than 2/3 of surface of uterus, and when more than 50% lies in intramural part, and involves the lateral wall. Score 0-4 comes under group 1 and the recommendation is low complexity hysteroscopic myomectomy, when the score is 5-6, recommendation is high complexity hysteroscopic myomectomy -GnRH/Two-step hysteroscopic myomectomy. If the score is above 7, hysteroscopic myomectomy is not indicated. 6 In present study 38 hysteroscopic myomectomies were undertaken. The patients' median age was 35 years (20 to 50). AUB being controlled in 89.48% of the patients in present study, similar to study by Wamsteker et al. 5 In this study bleeding was controlled in 48 (94.1%) of all patients after final resection. 5 Hysterectomy was performed in three patients (5.9%) because of persistent complaints: in two cases after incomplete resection and in one case after complete resection and 6.7% had a recurrence. In our study hysterectomy was performed in 1 woman, who was not willing for second resection. There was no recurrence in remaining women. As with more extensive intramural involvement, the chance to achieve complete resection decreases and the mean number of procedures to achieve complete resection increases. Complete resection improves the long-term results of transcervical resection of submucous fibroids for control of abnormal uterine bleeding. Transcervical resection of submucous fibroids with more than 50% intramural extension should be performed only in selected cases, as complete resection usually necessitates repeat procedures. Repeat resection is an option after failed primary hysteroscopic operation and may reduce the hysterectomy rate. In our series 4 women required second resection as they were in group 3 classification and were of size more than 8 cm. In another study after a follow-up period of five years and more, results were satisfactory in 70-85% of the patients. Prior to hysteroscopic myoma resection, pre-treatment with GnRH agonists was used in this study, as we also used in 8 cases. 7 It may be indicated in selected cases (large myoma, patients suffering from secondary anemia). The American College of Obstetricians and Gynecologists currently also recommends GnRH agonist therapy as a temporizing agent in women nearing menopause or as surgical pre-treatment in selected women. Preoperatively, GnRH agonists offer several advantages. Their use decreases menorrhagia and may allow correction of anemia. Decreased uterine size as a result of treatment may allow a less-complicated or extensive surgical procedure. Use of gonadotropin-releasing hormone (GnRH) agonists have been shown to improve hematologic parameters, shorten hospital stay, and decrease blood loss, operating time, and postoperative pain when given for 2-3 months preoperatively. Benefits of preoperative use of GnRH agonists should be weighed against their cost and side effects for individual patients. 8 Operative hysteroscopy is also safe and effective in controlling persistent postmenopausal bleeding and menorrhagia. [7] [8] [9] [10] [11] [12] In infertile women with sub mucosal or intracavitary fibroids, pregnancy and delivery rates are increased after hysteroscopic myomectomy. 7 Out of 11 patients in our study conceived within 1 year of resection and delivered at full term. In one study hysteroscopic myomectomy was associated with an increase in pregnancy rate 57.1% for patients with type 0 myoma and 42.8% for patients with type I myoma. Patients with type II myoma, after hysteroscopic myomectomy, had a 25% pregnancy rate, while patients who received expectant management had a 50% rate. Delivery at term was achieved by 35.7% of patients with type 0 myoma, by 28.5% of patients with type I myoma, and by 25% of patients with type II myoma, after hysteroscopic myomectomy. 13 Other studies also concluded that hysteroscopic leiomyoma resection also improves fertility rates, especially when tumors are the sole cause of infertility. [14] [15] [16] Even uterine artery embolization is an angiographic interventional procedure that delivers particulate emboli into both uterine arteries. Uterine blood flow is therefore obstructed, producing ischemia and necrosis. Embolization is effective for leiomyomarelated symptoms. The American college of obstetricians and gynaecologists currently recommends it for shortterm relief of bleeding or pressure symptoms. Newer modalities as magnetic resonance imaging-guided focused ultrasound (MRI-FUS) therapy is a safe and feasible, minimally invasive alternative for leiomyoma treatment. It may provide short-term symptom relief with the advantage of a quicker recovery and few major adverse events.
